Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease

Kidney International

Volumn 79, Issue 6, 2011, Pages 663-670

  Najafian, Behzad ^a   Svarstad, Einar ^b,c   Bostad, Leif ^c   Gubler, Marie Claire ^d   Tøndel, Camilla ^b,c   Whitley, Chester ^e   Mauer, Michael ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d INSERM   (France)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Fabry disease pathology; pediatric nephrology; podocyte; renal biopsy

Indexed keywords

GLOBOTRIAOSYLCERAMIDE;

ADOLESCENT; ADULT; AGE; ARTICLE; CELL DAMAGE; CELL INCLUSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIUM CELL; FABRY DISEASE; FEMALE; GLOMERULUS; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LIPID STORAGE; MALE; MESANGIUM CELL; PODOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; SCHOOL CHILD;

EID: 79952192786     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.484     Document Type: Article

References (36)

1. Colley JR, Miller DL, Hutt MS et al. The renal lesion in angiokeratoma corporis diffusum. Br Med J 1958; 1: 1266-1268.
2. Alroy J, Sabnis S, Kopp JB. Renal pathology in fabry disease. J Am Soc Nephrol 2002; 13: S134-S138. (Pubitemid 34579224)
3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750-760. (Pubitemid 33032930)
4. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-775. (Pubitemid 33032933)
5. Wilcox WR, Oliveira JP, Hopkin RJ. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008; 93: 112-128.
6. Schiffmann R, Warnock DG, Banikazemi M et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24: 2102-2111.
7. Sheth KJ, Roth DA, Adams MB. Early renal failure in Fabry's disease. Am J Kidney Dis 1983; 2: 651-654. (Pubitemid 13078643)
8. Tøndel C, Bostad L, Hirth A et al. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria [published erratum appears in Am J Kidney Dis 2009; 53: 567] Am J Kidney Dis 2008; 51: 767-776. (Pubitemid 351626251)
9. Fogo AB, Bostad L, Svarstad E et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010; 25: 2168-2177.
10. Branton MH, Schiffmann R, Sabnis SG et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122-138. (Pubitemid 34218568)
11. Schiffmann R, Ries M, Timmons M et al. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006; 21: 345-354. (Pubitemid 43159987)
12. Dehout F, Schwarting A, Beck M et al. Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data. Acta Paediatr 2003; discussion 5(Suppl 92): 14-15. (Pubitemid 38134743)
13. Schiffmann R, Askari H, Timmons M et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 2007; 18: 1576-1583. (Pubitemid 46717525)
14. West M, Nicholls K, Mehta A et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009; 20: 1132-1139.
15. Gubler MC, Lenoir G, Grunfeld JP et al. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 1978; 13: 223-235. (Pubitemid 8304328)
16. Fabry J. Ein beitrag zur kenntnis der purpura haemorrhagica nodularis (Purpura papulosa hemorrhagica Hebrae). Arch Dermatol Syphilis 1898; 43: 187-200.
17. Pompen AW, Ruiter M, Wyers HJ. Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports. Acta Med Scand 1947; 128: 234-255.
18. Desbois JC, Maziere JC, Gubler MC et al. Fabry's disease in children. Clinical and biological study of one family. Structure and ultrastructure of the kidney in a hemizygote and a heterozygote. Ann Pediatr (Paris) 1977; 24: 575-586.
19. Elleder M, Poupetova H, Kozich V. Fetal pathology in Fabry's disease and mucopolysaccharidosis type I. Cesk Patol 1998; 34: 7-12.
20. Desnick RJ, Allen KY, Desnick SJ et al. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 1973; 81: 157-171.
21. Tsutsumi O, Sato M, Sato K et al. Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected with Fabry's disease. Asia Oceania J Obstet Gynaecol 1985; 11: 39-45.
22. Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987; 147: 229-263.
23. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147. (Pubitemid 43882099)
24. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697.
25. Rademacher E, Mauer M, Jacobs DRJ et al. Albumin excretion rate in normal adolescents: relation to insulin resistance and cardiovascular risk factors and comparisons to type 1 diabetes mellitus patients. Clin J Am Soc Nephrol 2008; 3: 998-1005.
26. Torbjörnsdotter TB, Perrin NE, Jaremko GA et al. Widening of foot processes in normoalbuminuric adolescents with type 1 diabetes. Pediatr Nephrol 2005; 20: 750-758. (Pubitemid 40663157)
27. Germain DP, Waldek S, Banikazemi M et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007; 18: 1547-1557. (Pubitemid 46717522)
28. Thurberg BL, Rennke H, Colvin RB et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62: 1933-1946. (Pubitemid 35366149)
29. Lubanda JC, Anijalg E, Bzdúch V et al. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 2009; 11: 256-264.
30. Wanner C, Oliveira JP, Ortiz A et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry. Clin J Am Soc Nephrol 2010 [PMID:20813854; e-pub ahead of print].
31. Banikazemi M, Bultas J, Waldek S et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146: 77-86. (Pubitemid 351640010)
32. Toyoda M, Najafian B, Kim Y et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007; 56: 2155-2160. (Pubitemid 47195834)
33. Shu L, Park JL, Byun J et al. Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J Am Soc Nephrol 2009; 20: 1975-1985.
34. Caramori ML, Basgen JM, Mauer M. Glomerular structure in the normal human kidney: differences between living and cadaver donors. J Am Soc Nephrol 2003; 14: 1901-1903. (Pubitemid 36750487)
35. Caramori ML, Kim Y, Huang C et al. Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes [published erratum appears in Diabetes 2002; 51: 1294] Diabetes 2002; 51: 506-513. (Pubitemid 34764810)
36. Houser M. Assessment of proteinuria using random urine samples. J Pediatr 1984; 104: 845-848.